<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872950</url>
  </required_header>
  <id_info>
    <org_study_id>2001-040</org_study_id>
    <nct_id>NCT00872950</nct_id>
  </id_info>
  <brief_title>3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)</brief_title>
  <acronym>LEMS</acronym>
  <official_title>Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and adverse effects of
      3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and
      Congenital Myasthenic Syndromes (CMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized, non-comparative expanded access study. Up to 25
      patients with clinically proven paraneoplastic or primary autoimmune LEMS per EMG and
      positive voltage-gated calcium channel antibody serology, OR patients with clinically proven
      CMS per EMG, biopsy or genetic testing who meet the selection criteria outlined in sections
      3.1 and 3.2 will be enrolled in this study. Subjects will receive 3,4-DAP starting with a low
      dose and titrating up per efficacy and patient tolerance to a maximum daily dose of 100mg .
      Treatment will continue until the subject experiences a treatment-limiting toxicity,
      voluntarily withdraws consent, transfers to another site, dies, becomes lost to follow-up, is
      no longer receiving clinical benefit from 3,4-DAP (in the opinion of the subject and/or the
      investigator), or the Jacobus Pharmaceuticals or the FDA discontinues the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in strength and autonomic symptoms</measure>
    <time_frame>1-10 years</time_frame>
    <description>Patients will be monitored for strength and side effects. Treatment will be continued indefinitely if a good clinical response is achieved and side effects tolerable.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lambert-Eaton Myasthenic Syndrome</condition>
  <condition>Congenital Myasthenic Syndrome</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-DIAMINOPYRIDINE</intervention_name>
    <description>Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>3,4 DAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis

          -  18 years or older

          -  Females must have negative pregnancy test and be willing to practice an effective form
             of birth control

          -  No prolonged QT syndrome as indicated by baseline EKG

        Exclusion Criteria:

          -  Known sensitivity to 3,4-DIAMINOPYRIDINE

          -  History of seizures and/or severe asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayashri Srinivasan, MD,MCRP,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lahey.org</url>
    <description>Lahey Hospital &amp; Medical Center</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEMS</keyword>
  <keyword>CMS</keyword>
  <keyword>3,4 DIAMINOPYRIDINE</keyword>
  <keyword>3,4 DAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifampridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

